NCCN Adds Nirogacestat to Guidelines for Patients With Soft Tissue Sarcoma
The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.
Source: onclive.com